Key Takeaway: Avalyn has completed enrollment for its MIST global Phase 2b trial of AP01, involving 398 patients. The company anticipates topline data to be available in the second half of 2027. Additionally, two abstracts have been accepted for presentation at the upcoming European Respiratory Society Congress, showcasing data on AP01 lung tissue distribution.
Market Sentiment Analysis
POSITIVE FACTORS
Completed enrollment of the MIST global Phase 2b trial with 398 patients.
Topline data from the trial is expected in the second half of 2027.
Two abstracts accepted for presentation at the ERS Congress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~10 mo
Medium dilution risk
Lead asset
AP01
Phase 2 · Pulmonary Fibrosis
Full Press Release Details
Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress, including data modeling AP01 lung tissue distribution Ended the second quarter
Frequently Asked Questions
What trial did Avalyn complete enrollment for?
Avalyn completed enrollment for the MIST global Phase 2b trial of AP01.
How many patients were enrolled in the trial?
A total of 398 patients were enrolled in the trial.
When is the topline data expected?
Topline data from the trial is expected in the second half of 2027.
What presentations were accepted at the ERS Congress?
Two abstracts were accepted for presentation, including data on AP01 lung tissue distribution.